Health Canada has given the green light to a new GLP-1 weight-loss medication taken as a daily pill instead of a weekly injection. It has also been authorized for adults who are overweight and have at least one weight-related health condition, such as high blood pressure or sleep apnea, and it’s approved to help manage Type 2 diabetes. An Eli Lilly spokesperson said in a media statement that the company expects the pills to be available in pharmacies early in the New Year. The active ingredient in Foundayo is orforglipron, a non-peptide GLP-1 receptor agonist. A receptor agonist is a chemical or drug that attaches to a cell receptor and activates it, triggering a biological response. It is used for weight loss by mimicking natural gut hormones that tell your brain you are full, slow down digestion, and regulate blood sugar, according to Obesity Canada. GLP-1s have overhauled weight-loss treatment, shifting obesity care from short-term dieting to targeted biological treatment. A number of new options have arrived on the market in recent few years, including daily oral weight-loss pills and lower-cost generic injections. Competitor Novo Nordisk manufactures Ozempic and Wegovy, injectable drugs that contain the active ingredient semaglutide. Generic versions of semaglutide are sold in Canada by several other companies. Another GLP-1 pill, Novo Nordisk’s Rybelsus, is also available in Canada, but it is approved only to manage Type 2 diabetes—not for weight loss. Canada may soon have a second GLP-1 weight-loss pill option—Novo Nordisk’s Wegovy pill. It’s still awaiting Health Canada approval. Both Foundayo and the Wegovy pill have received approval in the United States and are currently available to patients there.